Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016

  • ID: 3802769
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athenex, Inc.
  • Basilea Pharmaceutica AG
  • Pfizer Inc.
  • MORE
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016

Summary

‘Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016’, provides in depth analysis on Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2)
- The report reviews Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athenex, Inc.
  • Basilea Pharmaceutica AG
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Overview

Therapeutics Development

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Products under Development by Stage of Development

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Products under Development by Therapy Area

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Products under Development by Indication

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Products under Development by Companies

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Products under Development by Universities/Institutes

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Advenchen Laboratories, LLC

Athenex, Inc.

Basilea Pharmaceutica AG

Pfizer Inc.

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Drug Profiles

apatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-196969 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-241161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eCF-506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecules to Inhibit Src Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Src Tyrosine Kinase for Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UM-164 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Dormant Projects

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Discontinued Products

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Featured News & Press Releases

Jun 08, 2016: New compound shows potential for triple-negative breast cancer

May 23, 2016: Breast cancer drug discovery offers hope of new treatments

Sep 15, 2015: Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

Feb 18, 2015: Particle Sciences Manufactures Clinical Supplies for Kinex's Glioblastoma Therapeutic

Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study

Dec 24, 2014: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study

Dec 09, 2014: Pfizer Demonstrates New Data On BOSULIF at ASH 2014

Aug 11, 2014: Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

Jul 24, 2014: Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)

Mar 30, 2014: Atlantic Research Group Client Kinex Pharmaceuticals Initiate Phase I Glioblastoma trial

Jan 09, 2014: Avillion Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

Dec 04, 2013: Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas

Jul 16, 2013: NICE consults on a new treatment for chronic myeloid leukaemia

Jun 04, 2013: Kinex Pharma Receives IND Approval From FDA For KX02 Clinical Trials In Brain Tumor Patients

Mar 28, 2013: Pfizer’s Bosulif Receives Conditional Marketing Authorization From European Commission

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 60List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Advenchen Laboratories, LLC, H1 2016

Pipeline by Athenex, Inc., H1 2016

Pipeline by Basilea Pharmaceutica AG, H1 2016

Pipeline by Pfizer Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 48List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Athenex, Inc.
  • Basilea Pharmaceutica AG
  • Pfizer Inc.
  • MORE
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) pipeline Target constitutes close to 12 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Tyrosine-Protein Kinase CSK - Pipeline Review, H1 2016, outlays comprehensive information on the Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR). The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Furthermore, this report also reviews key players involved in Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Advenchen Laboratories, LLC
Athenex, Inc.
Basilea Pharmaceutica AG
Pfizer Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll